Interactive tool · FDA prescribing information anchored

Brand-Switch Dose-Equivalence Calculator

Switching from one weight-loss GLP-1 drug to another? This tool surfaces the FDA-label dose ladders, re-titration rules, and cross-trial efficacy data for all four FDA-approved chronic-weight-management GLP-1 medications — Wegovy, Zepbound, Foundayo, and Saxenda — so you walk into your prescriber appointment better informed.

Medical disclaimer — read before using this tool

This tool does not provide medical advice. It is a patient-education aid that surfaces verbatim FDA-label dose information and published trial data. Brand-switch decisions — including starting dose, timing, and washout — must be made with and by a licensed prescriber. There is no FDA-approved dose-equivalence conversion between any of the four drugs listed here. Weight loss percentages are from independent phase 3 trials with different populations; they are not head-to-head equivalences. Compounded semaglutide and compounded tirzepatide are not FDA-approved; their dose ladders may differ from FDA-label doses.

Step 1 — Select your current drug and destination drug

Current drug (leaving)

Destination drug (switching to)

Select your current drug above to unlock the destination selector.

About this tool

This tool covers the four FDA-approved medications indicated for chronic weight management in adults:

Wegovy (semaglutide 2.4 mg weekly injection, Novo Nordisk) — FDA-approved June 2021; HD 7.2 mg tier approved March 2026
Zepbound (tirzepatide weekly injection, Eli Lilly) — FDA-approved November 2023
Foundayo (orforglipron once-daily oral tablet, Eli Lilly) — FDA-approved April 2026
Saxenda (liraglutide 3 mg daily injection, Novo Nordisk) — FDA-approved December 2014

Mounjaro (tirzepatide for T2D) and Ozempic (semaglutide for T2D) are not included because they carry a diabetes indication, not a primary obesity indication — their dose ladders are listed in the GLP-1 Titration Planner.

All dose ladders are sourced verbatim from FDA-approved prescribing information via DailyMed (NIH). DailyMed SetIDs: Wegovy (ee06186f-2aa3-4990-a760-757579d8f77b); Zepbound (487cd7e7-434c-4925-99fa-aa80b1cc776b); Foundayo (8ac446c5-feba-474f-a103-23facb9b5c62); Saxenda (3946d389-0926-4f77-a708-0acb8153b143).

Related tools

Related research

Medical disclaimer

This tool is for patient education only. It does not constitute medical advice, diagnosis, or a treatment recommendation. All brand-switch, dose, and timing decisions must be made with a licensed prescriber who can review your complete medical history, comorbidities, current medications, and insurance coverage. FDA-label dose ladders represent minimum titration intervals; your prescriber may individualize these based on tolerability. There is no FDA-approved dose-equivalence conversion between any of the four drugs in this tool. Cross-trial efficacy comparisons are not head-to-head data (except SURMOUNT-5 for Zepbound vs Wegovy). Compounded versions of semaglutide and tirzepatide are not FDA-approved products; consult your prescriber and compounding pharmacy for their specific dose ladders.